Aug 13 |
et al., European Journal of Medical Research, doi:10.1186/s40001-024-02008-x | Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID) |
| 17% higher mortality (p=0.7), 2% lower progression (p=1), and 9% longer ventilation (p=0.62). RCT 166 severe COVID-19 patients on non-invasive ventilation or high-flow oxygen showing no significant difference in clinical deterioration or mortality with trimodulin treatment compared to placebo. In a post hoc analysis of a subgroup .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.